No Incidence of BRAF Mutations in Salivary Gland Carcinomas—Implications for Anti-EGFR Therapies

BRAF is the main effector of KRAS in the RAS-RAF-MAPK axis, a signaling pathway downstream of EGFR. The activation of this cascade is an important pathway in cancer development and is considered a key pathway for therapeutic molecules. Recent studies in metastatic colorectal cancer found that an onc...

Descripción completa

Detalles Bibliográficos
Autores principales: Dahse, Regine, Kromeyer-Hauschild, Katrin, Berndt, Alexander, Kosmehl, Hartwig
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699443/
https://www.ncbi.nlm.nih.gov/pubmed/19547661
http://dx.doi.org/10.1155/2009/501736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2699443/
https://www.ncbi.nlm.nih.gov/pubmed/19547661
http://dx.doi.org/10.1155/2009/501736

Ejemplares similares